Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO), a leader in next-generation vision technology, announced highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The clinical outcomes exceed expectations, with all patients continuing to demonstrate improved vision and stable visual acuity, alongside a strong safety profile.
Six months after surgery, patients who entered the study with severely impaired vision, including one individual considered legally blind, have experienced real-world transformation in their daily lives. Anecdotally, all patients reported life-changing results from the lens implantations, with improvements such as reading, driving, and living independently again. These quality-of-life improvements underscore the profound impact of the technology beyond clinical metrics.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “Patients who entered this study with severely impaired vision are now reading, driving, and living independently again. We’re developing a technology that dramatically improves people’s quality of life and we couldn’t be happier.”
The company continues to leverage surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries. The forward momentum reinforces the expected performance of Ocumetics’ inaugural accommodating intraocular lens.
“The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns. “We are not only validating our technology, we are demonstrating its real-world impact. Our focus now is to build on this success, further optimize performance, and bring this life-changing solution to more patients.”
Ocumetics looks forward to initiating Group Two surgeries following completion of lens testing, as the company continues to advance its mission of transforming vision correction through innovation. The company will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month study results and important updates on the FIH study. Registration is available at www.ocumetics.com/webinar.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions that enhance quality of life. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies. The company is in the first-in-human early feasibility study phase of a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses by allowing the eye’s natural muscle activity to shift focus from distance to near.
